Literature DB >> 2642303

Prognostic variables in osteosarcoma: a multi-institutional study.

W F Taylor1, J C Ivins, K K Unni, J W Beabout, H J Golenzer, L E Black.   

Abstract

This is a report of a multi-institutional study of all patients with osteosarcoma who were seen at 13 comprehensive cancer centers from July 1, 1977, to December 31, 1982. Follow-up extended to 9 years; a minimum of 3 years was obtained for greater than 90% of the patients. All patients with osteosarcoma were considered, but only those with tissue confirmation who had had at least part of their first course of treatment at one of the 13 institutions were included. There were 543 patients. In a search for prognostic indicators, 38 patient characteristics, three treatment categories, and an institutional variable were studied. A combination of nine of these constituted the best indicator of survival. They were morphology (two parts), site of primary cancer (two parts), spread of tumor, grade and size of tumor, duration of symptoms, weight loss of greater than 4.5 kg (10 lb), swelling at primary site, and lytic appearance. Unexpectedly, treatment was not one of the indicators of survival. A prognostic score was developed in which the coefficients were obtained from the Cox regression (step-down) method. Each patient had a score (S) and an observed survival time that together provided the expected risk of death for that patient. Although this was not a randomized study, treatments were compared before and after adjusting for characteristics identified as prognostic. Three treatments differed little: surgery alone, surgery plus chemotherapy and/or radiotherapy, and chemotherapy and/or radiotherapy followed in 1-4 months by surgery. Patients with amputations and those with resections had similar death rates, but the observed progression rates differed widely. However, when the rates were adjusted for prognostic characteristics, the difference disappeared. Complete surgery (if osteosarcoma existed within surgical margins) was no better than incomplete surgery (if osteosarcoma existed beyond surgical margins) with respect to death but, as would be expected, complete surgery was much better with respect to disease progression.

Entities:  

Mesh:

Year:  1989        PMID: 2642303     DOI: 10.1093/jnci/81.1.21

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  Local growth and the prognosis of osteosarcoma.

Authors:  P Wuisman; W F Enneking; A Roesner
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

2.  Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Authors:  Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer
Journal:  Int Orthop       Date:  2010-03-26       Impact factor: 3.075

3.  The effect of preoperative radiotherapy on local control and prognosis in high-grade non-metastatic intramedullary osteosarcoma of the extremities.

Authors:  Bedri Karaismailoglu; Murat Hız; Suat Ulutas; Vedat Burkay Camurdan; Baris Gorgun; Fazilet Oner Dincbas
Journal:  Arch Orthop Trauma Surg       Date:  2020-06-06       Impact factor: 3.067

4.  Expression change of ezrin as a prognostic factor in primary osteosarcoma.

Authors:  Yao Fei Wang; Jing Nan Shen; Xian Biao Xie; Jin Wang; Gang Huang
Journal:  Med Oncol       Date:  2010-09-22       Impact factor: 3.064

5.  Biopsy technique in the treatment of osteosarcoma.

Authors:  J A Cara del Rosal; J Cañadell
Journal:  Int Orthop       Date:  1994       Impact factor: 3.075

6.  Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.

Authors:  Sébastien Salas; Catherine Bartoli; Jean-Laurent Deville; Jean Gaudart; Fréderic Fina; Arlette Calisti; Gérard Bollini; Georges Curvale; Jean-Claude Gentet; Florence Duffaud; Dominique Figarella-Branger; Corinne Bouvier
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

7.  Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

Authors:  Liliana Vasquez; Fanny Tarrillo; Monica Oscanoa; Ivan Maza; Jenny Geronimo; Gloria Paredes; Jose María Silva; Luis Sialer
Journal:  Front Oncol       Date:  2016-02-02       Impact factor: 6.244

8.  Association between Body Condition Score and Cancer Prognosis in Dogs with Lymphoma and Osteosarcoma.

Authors:  F R Romano; C R Heinze; L G Barber; J B Mason; L M Freeman
Journal:  J Vet Intern Med       Date:  2016-06-08       Impact factor: 3.333

9.  Antitumor Effect of Sclerostin against Osteosarcoma.

Authors:  Hirokazu Ideta; Kazushige Yoshida; Masanori Okamoto; Jun Sasaki; Munehisa Kito; Kaoru Aoki; Yasuo Yoshimura; Shuichiro Suzuki; Atsushi Tanaka; Akira Takazawa; Hisao Haniu; Takeshi Uemura; Takashi Takizawa; Atsushi Sobajima; Takayuki Kamanaka; Jun Takahashi; Hiroyuki Kato; Naoto Saito
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

10.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.